### ABCA4-Related Retinopathies in Lebanon: a novel mutation and significant heterogeneity

Mariam Ibrahim <sup>4,5</sup>, Lama Jaffal <sup>2</sup><br>Hassan Rammal Research Labora<br>Nabatieh, Lebanon.<br>ent of Biological and Chemical So<br>Beirut, Lebanon. , Alexandre Assi<br>story, PhyToxE Re<br>ciences, School of , Charles Helou<br>search Group, Fa<br>Arts and Science , Said El Shamieh<sup>-</sup><br>aculty of Sciences,<br>es, Lebanese Inter 1 Rammal Hassan Rammal Research Labor, PhyToxE Research Group, Passan, Prosences, Lemmer, 2014<br>1 Repartment of Biological and Chemical Sciences, School of Arts and Sciences, Lebanese International<br>1 Retinal Service, Beirut

2 Department of Biological and<br>University, Beirut, Lebanon.<br>3 Beirut Eye Clinic, Beirut, Leban<br>4 Retinal Service, Beirut Eye & E<br>5 Medical Testing Laboratory, D<br>Sciences, Beirut Arab University

3 Beirut Eye Clinic, Beirut, Le<br>4 Retinal Service, Beirut Eye<br>5 Medical Testing Laboratory<br>Sciences, Beirut Arab Univer

4 Retinal Service, Beirut Eye & ENT S<br>5 Medical Testing Laboratory, Depar<br>Sciences, Beirut Arab University, Bei

2 Department of Department of Department of Nedical Arts and Chemical Seirut Eye Clinic, Beirut, Lebanon.<br>2 Beirut Eye Clinic, Beirut Eye & ENT Specialist Hospital, Beirut, Lebanon.<br>5 Medical Testing Laboratory, Department 4 Andrew Constitution Construction Service, Andren Sciences, Beirut Arab University, Beirut, Lebanon.<br>Sciences, Beirut Arab University, Beirut, Lebanon.<br>\*Correspondence:

5 Medical Testing Laboratory, Department of Medical Laboratory, Technology, Faculty of Medical<br>Sciences, Beirut Arab University, Beirut, Lebanon<br>\*Correspondence:<br>Said El Shamieh PhD. s.elshamieh@bau.edu.lb

\*Correspondence:

Sciences, Beitart Arab University, Beitarten<br>\*Correspondence:<br>Said El Shamieh PhD. <u>s.elshamieh@bau.edu.lb</u> Said El Shamieh PhD. s.elshamieh@bau.edu.lb

#### Abstract

inherited retinal diseases (IRDs) besides the classically defined Stargardt disease (STGD), known as<br>ABCA4 retinopathies. ABCA4 is a sizeable locus harboring 50 exons; thus, its analysis has revealed a rich<br>area of genetic ABCA4 retinopathies. ABCA4 is a sizeable locus harboring 50 exons; thus, its analysis has revealed a rich<br>area of genetic information comprising at least 1,200 disease-causing mutations of varied severity and<br>types. Due to ABCA4 retinopation comprising at least 1,200 disease-causing mutations of varied severity and<br>types. Due to the clinical and genetic heterogeneity, diagnosing ABCA4 retinopathies is challenging. To<br>date, no ABCA4-retinopat types. Due to the clinical and genetic heterogeneity, diagnosing *ABCA4* retinopathies is challenging. To<br>date, no *ABCA4*-retinopathy has been detected in Lebanon. Using next-generation sequencing, we<br>sought to pinpoint t the clinical and and general and general and general process. The clinical and the clinical and sequencing, we<br>sought to pinpoint the mutation spectrum in seven families with different forms of IRDs: STGD, rod-cone<br>and con date, no ABCA4-retinopathy has been detected in Lebanon Lebanon and generation sequencing, increased and cone-rod dystrophies (RCD and CRD, respectively). Eight *ABCA4* mutations were found, including one novel; c.4330G>C; source in the mutations (RCD and CRD, respectively). Eight *ABCA4* mutations were found, including<br>one novel; c.4330G>C; p.(Trp1408Cys). Three families were diagnosed with CRD, two with STGD, and<br>two others with RCD. In co one novel; c.4330G>C; p.(Trp1408Cys). Three families were diagnosed with CRD, two with STGD, and<br>two others with RCD. In conclusion, our study revealed a novel ABCA4 mutation and showed significant<br>genotypic and phenotypic one novel is not the none in the summer that any the state with the state with RCD. In conclusion, our study revealed a novel ABCA4 mutation and showed significant genotypic and phenotypic heterogeneity in Lebanon.<br>Keyword two others with RCD. In conclusion, our study revealed a novel ABC mutation and showed a novel ABCA4 mutations<br>Reywords: ABCA4, inherited retinal dystrophies, retinopathies, Lebanon, mutations.

Keywords: *ABCA4*, inherited retinal dystrophies, retin<br>**Keywords:** *ABCA4*, inherited retinal dystrophies, retin  $\overline{a}$ Keywords: ABCA4, inherited retinal dystrophies, retinopathies, Lebanon, mutations.

#### Introduction

Interaction or impairment [1, 2]. These diseases are well defined by a high degree of clinical and<br>genetic variation, with over 270 genes implicated [1]. Interestingly, the age of onset, the progression<br>rate, manifestation genetic variation, with over 270 genes implicated [1]. Interestingly, the age of onset, the progression<br>rate, manifestation with extra-ocular symptoms, and the etiological gene may assist in classifying IRDs<br>into more than general channels, that then are generally properties (a). There ends, the progressiving IRDs<br>into more than 20 distinct phenotypes [3, 4]. The most prevalent form of IRDs is rod-cone dystrophy<br>(RCD; MIM 613862), which affe rate, many of the most prevalent form of IRDs is rod-cone dystrophy<br>(RCD; MIM 613862), which affects over one million individuals worldwide and is defined by the primary<br>death of rods subsequently accompanied by secondary INCO; MIM 613862), which affects over one million individuals worldwide and is defined by the primary<br>death of rods subsequently accompanied by secondary deterioration of cone photoreceptors [3, 5].<br>When cone photoreceptor (RCD) MIM 613862), MIM 613862, MIM 6138762, MIM 611771, MIM 611771, MIM 611777), represented by rod dysfunction in later stages, this is called cone-rod dystrophy (CRD; MIM 601777), represented by progressive degeneration When cone photoreceptor degeneration occurs initially, followed by rod dysfunction in later stages, this<br>is called cone-rod dystrophy (CRD; MIM 601777), represented by progressive degeneration and loss of<br>the central retin Is called cone-rod dystrophy (CRD; MIM 601777), represented by progressive degeneration and loss of<br>the central retina [6, 7]. Other aspects of IRDs that appear with central vision loss include macular<br>dystrophies (MD) tha is cance the contract cone-part of the yranger of IRDs that appear with central vision loss include macular dystrophies (MD) that affect mainly the macula [3, 7]. With an incidence rate of 1 in 8,000–10,000 individuals, St dystrophies (MD) that affect mainly the macula [3, 7]. With an incidence rate of 1 in 8,000–10,000<br>individuals, Stargardt disease (STGD; MIM 248200) emerges as the prevailing aspect of MD with an<br>autosomal recessive mode o diminity of the matrice of STGD; MIM 248200) emerges as the prevailing aspect of MD with an<br>autosomal recessive mode of inheritance affiliated with etiological mutations in the ATP-binding<br>cassette transporter type A4 (ABC

autosomal recessive mode of inheritance affiliated with etiological mutations in the ATP-binding<br>cassette transporter type A4 (ABCA4) [8].<br>Since the 1997 identification of the ABCA4 gene by Allikmets and colleagues, more t cassette transporter type A4 (*ABCA4*) [8].<br>Since the 1997 identification of the *ABCA4* gene by Allikmets and colleagues, more than 1,200 distinct<br>disease-causing mutations of varying severity have been reported [9-11]. Since the 1997 identification of the *ABCA*<br>disease-causing mutations of varying sev<br>associated with phenotypes other t<br>flavimaculatus, age-related MD, and so<br>significant disparities in disease-causing<br>mutations in differe ؟<br>C<br>f<br>r Since the 1997 in the 1997 in the 1997 in the 1997 in the ABCA4 variations have been<br>disease-causing mutations of varying severity have been reported [9-11]. ABCA4 variations have been<br>associated with phenotypes other than diseased with phenotypes other than the commonly recognized STGD, including fundus<br>flavimaculatus, age-related MD, and some forms of CRD and RCD [9, 10]. The ABCA4 locus shows<br>significant disparities in disease-causing all Flavimaculatus, age-related MD, and some forms of CRD and RCD [9, 10]. The *ABCA4* locus shows<br>significant disparities in disease-causing alleles across racial and ethnic groups and exhibits founder<br>mutations in different significant disparities in disease-causing alleles across racial and ethnic groups and exhibits founder<br>mutations in different populations [11]. Considering the massive clinical and genetic heterogeneity, an<br>accurate and t significant disparition in different populations [11]. Considering the massive clinical and genetic heterogeneity, an<br>accurate and thorough molecular diagnosis of *ABCA4*-associated retinopathies is critical [12]. However, mutations in anti-care populations (11). Contracting the interior antitial and generations cliental, and<br>accurate and thorough molecular diagnosis of ABCA4-associated retinopathies is critical [12]. However,<br>the allelic he <sup>2</sup><br>
accurate and these gene-associated IRDs very<br>
challenging [13]. Direct Sanger sequencing of all *ABCA4* exons (50 exons) has uncovered between 60%-<br>
80% of the pathogenic alleles [12]. Notably, next-generation sequenc challenging [13]. Direct Sanger sequencing of all *ABCA4* exons (50 exons) has uncovered between 60%-<br>80% of the pathogenic alleles [12]. Notably, next-generation sequencing (NGS) platforms have proven to<br>find novel *ABCA4* 80% of the pathogenic alleles [12]. Notably, next-generation sequencing (NGS) platforms have proven to find novel ABCA4 mutations, demonstrating their ability as more comprehensive approaches for systematic genetic screeni Find novel *ABCA4* mutations, demonstrating their ability as more comprehensive approaches for systematic genetic screening of large cohorts [14, 15]. Presently, NGS is critical for obtaining a prompt and precise genetic d find the comprehensive and flarge cohorts [14, 15]. Presently, NGS is critical for obtaining a prompt<br>and precise genetic diagnosis, which is required to provide patients and their families with the<br>appropriate genetic cou systematic generations of large control [14, 15]. Presently, NGS is intital for large appropriate genetic diagnosis, which is required to provide patients and their families with the appropriate genetic counseling [1, 16]. appropriate genetic counseling [1, 16]. The relevance of genetic diagnosis through the implementation<br>of comprehensive and affordable sequencing technologies lies in identifying the disease-causing<br>3 appropriate and affordable sequencing technologies lies in identifying the disease-causing  $\frac{3}{3}$ of comprehensive and affordable sequencing technologies lies in identifying the distribution of a<br>a<br>causing the disease-causing technologies lies in identifying the distribution of a

interpretation of the pathophysiological mechanisms, and tailoring the approach of personalized<br>therapy [5]. Many *ABCA4* mutations associated with different forms of IRDs have been reported<br>worldwide, but none in Lebanon. therapy [5]. Many *ABCA4* mutations associated with different forms of IRDs have been reported worldwide, but none in Lebanon. Herein, the aim was to detect causative *ABCA4* mutations in Lebanese patients from seven famil worldwide, but none in Lebanon. Herein, the aim was to detect causative  $ABCAA$  mutations in Lebanese<br>patients from seven families diagnosed with varying forms of IRDs.<br> $\frac{1}{2}$ patients from seven families diagnosed with varying forms of IRDs.<br>
Alternative ABCA4 mutations in Lebanon. Herein, the aim was to detect causative ABCA4 mutations in Lebanese A<br>
The aim was to detect causations in Lebanes patients from seven families diagnosed with varying forms of IRDs.

#### Materials and Methods:

#### Ethical considerations and Clinical Examinations:

Institutional review board under the IRB number 2017 H-0030-HS-R-0208 granted ethical approval. All<br>
our participants were recruited at Beirut Eye and ENT Specialist Hospital (Lebanon) where they received<br>
carried out a cl Institutional review board and the IRB number 2017 in the IRB number board optical summington and provided (Lebanon) where they received<br>carried out a clinical ophthalmologic assessment and provided informed written consen carried out a clinical ophthalmologic assessment and provided informed written consent before<br>participation, as previously described [17].<br>Mutational Screening<br>All our participants gave whole blood samples. Genomic DNA ext

#### Mutational Screening

participation, as previously described [17].<br>participation, as previously described [17].<br>Mutational Screening<br>All our participants gave whole blood samples. Genomic DNA extraction was done by Qiagen's QlAamp<br>DNA Mini Kit participation, as previously decembed [17].<br>Mutational Screening<br>All our participants gave whole blood sam<br>DNA Mini Kit (Hilden, Germany). Whole e<br>samples of all the indexes except F3:13 a<br>previously [15]. Common polymorph 「ノ」 にっぽん しょうしょう こうしょう こうしゃ しんりょう しょうしょう しょうしょう しょうしゃ しょうしゃ All our participants gave whole blood samples. Genomic DNA extraction was done by Qiagen's QlAamp<br>DNA Mini Kit (Hilden, Germany). Whole exome sequencing (WES) was executed to inspect the DNA<br>samples of all the indexes exce Samples of all the indexes except F3:13 and F9:19.1, sequenced through targeted NGS as described<br>previously [15]. Common polymorphisms that had a minor allele frequency (MAF) greater than 0.01<br>were all omitted using variou previously [15]. Common polymorphisms that had a minor allele frequency (MAF) greater than 0.01<br>were all omitted using various public databases, including GnomAD<br>(https://gnomad.broadinstitute.org/) [18]. This step was fol previously and the minority of the minority (https://gnomad.broadinstitute.org/) [18]. This step was followed by annotation type-based filtrat were were removed in-frame Indels, intronic mutations, synonymous mutations, and variations in<br>untranslated regions. Contrariwise, priority was given to mutations in exons or splice sites that resulted<br>in nonsense, missens (a) the constraints of the constant of the Candidate Mutations, synonymous mutations, and variations in<br>untranslated regions. Contrariwise, priority was given to mutations in exons or splice sites that resulted<br>in nonsense untranslated regions. Contrariwise, priority was given to mutations in exons or splice sites that resulted<br>in nonsense, missense variations, or frameshift Indels. Next, we checked whether the candidate<br>mutations were repor untranslated regions of translations, or frameshift Indels. Next, we checked whether the candidate<br>in nonsense, missense variations, or frameshift Indels. Next, we checked whether the candidate<br>mutations were reported as h

#### Pathogenicity assessment of the Candidate Mutations

in nonsense, missense variations, or ministense variations, or misses means when the candidate<br>mutations were reported as homozygous in GnomAD.<br>The conservation of substituted amino acids in various species, such as primat Pathogenicity assessment of the Candidate Mutation:<br>The conservation of substituted amino acids in vario<br>mammals, was checked using the University of Califo<br>Information regarding the details was previously desc<br>substitutio The conservation of substitution amino and the conservation of substitution regarding the details was previously described [20]. The possible effect of the amino acid substitution was assessed by scale-invariant feature tr Information regarding the details was previously described [20]. The possible effect of the amino acid<br>substitution was assessed by scale-invariant feature transform (SIFT) [21], Polymorphism Phenotyping<br>v2 (PolyPhen-2) [2 Information was assessed by scale-invariant feature transform (SIFT) [21], Polymorphism Phenotyping<br>
V2 (PolyPhen-2) [22], and MutationTaster2 [23]. Several public databases were utilized to determine if<br>
the candidate mut substitution was assessed by Several public databases were utilized to determine if<br>the candidate mutation causing IRD was previously known [24], [25].<br>Segregation Analysis<br>The candidate mutations detected by NGS were ampl

#### Segregation Analysis

value of the candidate mutation causing IRD was previously known [24], [25].<br> **Segregation Analysis**<br>
The candidate mutations detected by NGS were amplified by conventional polymerase chain reaction<br>
(T100, Biorad, Kaki Bu Segregation Analysis<br>The candidate mutations detected by NGS were amplified by convert<br>T100, Biorad, Kaki Bukit, Singapore) and then validated (Applied E The candidated (Applied Biosystems 3730xl DNA Sequencer,<br>The capacity of Applied Biosystems 3730xl DNA Sequencer,<br>5  $(110)$  Biorad, Andrew Singapore) and then validated (Applied Biosystems 3730xl DNA Sequencer,  $\frac{1}{2}$ 

purpose, unidirectional Sanger sequencing was applied to all available family members' DNA.<br>purpose, unidirectional Sanger sequencing was applied to all available family members' DNA. purpose, unidirectional Sanger sequencing was applied to all available family members' DNA.

#### Results

#### Ophthalmic data

The current study in the current study in the current study in the current study in the posterior<br>
studies (Figure 1). Color fundus photographs of F3:13 revealed mild pigmentary changes in the posterior<br>
pole and outside t 2, induction and outside the vascular arcades (Figure 2a). Fluorescein angiography showed granular hyperfluorescence in the posterior pole with focal hyperfluorescence at the macula (Figure 2b).<br>Additionally, optical coher pole and outside the vascular arcades (Figure 2a). Fluorescein angiography showed granular<br>hyperfluorescence in the posterior pole with focal hyperfluorescence at the macula (Figure 2b).<br>Additionally, optical coherence tom pore and outside the vascular arcades (Figure 2a). And the vascular angiography continuate the vascular physodenesis<br>Additionally, optical coherence tomography (OCT) exhibited diffuse thinning of the retinal layers (Figure Additionally, optical coherence tomography (OCT) exhibited diffuse thinning of the retinal layers (Figure 2c).<br>2c). Electrooculogram (EOG) demonstrated no light rise and a subnormal Arden ratio of 1.68 on the right<br>eye and 2c). Electrooculogram (EOG) demonstrated no light rise and a subnormal Arden ratio of 1.68 on the right<br>eye and a reduced Arden ratio of 1.51 on the left eye, which are below the normal value (>1.8);<br>electroretinogram (ER 2c). Electrooculogram (EOG) demonstrated no light rise and a subnormal Arden ratio of 1.68 on the right<br>eye and a reduced Arden ratio of 1.51 on the left eye, which are below the normal value (>1.8);<br>electroretinogram (ERG

electroretinogram (ERG) revealed reduced scotopic and photopic responses (data not shown).<br>The index of family 9 does not have any previous cases in her family. In her 20s, she received a diagnosis<br>of CRD, and her OCT reve electroreting. The index of family 9 does not have any previous cases in her family. In her 20s, she received a<br>of CRD, and her OCT revealed thinning of the retinal layers at the macula in both eyes (Figure<br>demonstrated no ן<br>ג<br>t The independent of CRD, and her OCT revealed thinning of the retinal layers at the macula in both eyes (Figure 2c). ERG<br>demonstrated normal photopic and very reduced scotopic responses (data not shown). Moreover, EOG<br>displ of CRD, and the responses (data not shown). Moreover, EOG<br>displayed a normal Arden ratio of 2 on the right eye and a significantly subnormal Arden ratio of 1.6 on<br>the left eye.<br>F31:131, diagnosed with RCD in their 20s with

displayed a normal Arden ratio of 2 on the right eye and a significantly subnormal Arden ratio of 1.6 on<br>the left eye.<br>F31:l31, diagnosed with RCD in their 20s with no known family history. Color fundus photography of this displayed a normal Arthleticky.<br>F31:131, diagnosed with RCD in their 20s with no known family history. Color fundus photography of this<br>patient showed mild pigmentary changes in the posterior pole and outside the vascular the left eye. F31:I31 exhibited reduced photopic and subside the vascular arcades (Figure 2a). His autofluorescence examination showed increased hyperfluorescence at the macula (Figure 2d).<br>Besides, the ERG of this individual demonstrat patient showed increased hyperfluorescence at the macula (Figure 2d).<br>
Besides, the ERG of this individual demonstrated reduced photopic and significantly reduced scotopic<br>
responses. Additionally, F31:131 exhibited reduce 24). His antitude examination in the macula (Figure 2014) at the macula (Figure 2d).<br>Besides, the ERG of this individual demonstrated reduced photopic and significantly reduced scotopic<br>responses. Additionally, F31:131 exh

Besides, the ERG of this patient individual demonstrated reduced EOG with an Arden ratio of 1.29 on the right eye and<br>1.25 on the left eye (data not shown).<br>Index F37:137, issued from a consanguineous marriage, and was dia responses. And the left eye (data not shown).<br>
Index F37:I37, issued from a consanguineous marriage, and was diagnosed with CRD in their 30s. Clinical<br>
findings of this patient indicated reduced photopic and scotopic ERG r Index F37:137, issued from a consangu<br>
findings of this patient indicated redu<br>
this patient exhibited a reduced Arde<br>
(data not shown). Color photographs r<br>
2a). OCT scans showed thinning of th |
|
|
| Indings of this patient indicated reduced photopic and scotopic ERG responses. Moreover, the EOG of this patient exhibited a reduced Arden ratio of 1.25 and 1.24 on the right and left eyes, respectively (data not shown). C findings of this patient indicated reduced photopic indicated reduced and the response of this patient exhibited a reduced Arden ratio of 1.25 and 1.24 on the right and left eyes, respectively (data not shown). Color photo this patient and the reduced Arden ratio of 1.25 and 1.24 on the right and left eyes, respectively<br>(data not shown). Color photographs revealed optic disc parlor and atrophy in the posterior pole (Figure<br>2a). OCT scans sho (data). OCT scans showed thinning of the retinal layers and hyper-reflectivity at the level of the choroid<br>(Figure 2c). 2. Oct scans showed the retinal layers and hyper-reflectivity at the reflectivity at the choroid of th  $\sum_{i=1}^{n}$ 

|
|
|
| Family 12 eminions entrologinally particles parents in intertional constant of exhibited pigmentary changes in<br>has an affected descendant, F41:141. Color fundus examination showed marked pigmentary changes in<br>the posterior the posterior pole with marked vascular attenuation and optic disc pallor (Figure 2a). Additionally, OCT<br>demonstrated diffuse thinning of the retinal layers with cystic changes and focal scarring (Figure 2c). The<br>ERG displ

the monstrated diffuse thinning of the retinal layers with cystic changes and focal scarring (Figure 2c). The<br>ERG displayed a diminished photopic and scotopic responses. The clinical findings indicated a CRD.<br>Parents in fa demonstrated animished photopic and scotopic responses. The clinical findings indicated a CRD.<br>Parents in family 56 are phenotypically normal but have an affected descendant, F56:156, diagnosed<br>with STGD in their 20s. Her Parents in family 56 are phenotypically normal but have an affected descendant, F56:156, diag<br>with STGD in their 20s. Her color photograph showed an abnormal reflex at the macula (Figure<br>Besides, fluorescein angiography re |
|
|
|
| Parents in family 56 are phenotypically normal but have an abnormal reflex at the macula (Figure 2a).<br>
Besides, fluorescein angiography revealed increased hyperfluorescence at the macula (Figure 2b).<br>
Clinical diagnosis of Besides, fluorescein angiography revealed increased hyperfluorescence at the macula (Figure 2b).<br>Clinical diagnosis of F56:156 revealed macular dystrophy with relative preservation of macular<br>function. ERG of this patient Clinical diagnosis of F56:156 revealed macular dystrophy with relative preservation of macular<br>function. ERG of this patient demonstrated slightly reduced photopic and scotopic responses (data not<br>shown). Additionally, vis

Enneth angles of this patient demonstrated slightly reduced photopic and scotopic responses (data not<br>shown). Additionally, visual evoked potentials (VEP) was reduced for a small pattern.<br>Index F58:I58 has phenotypically n function. Additionally, visual evoked potentials (VEP) was reduced for a small pattern.<br>
Index F58:158 has phenotypically non-affected parents, but she was diagnosed clinically with RCD. ERG<br>
revealed reduced photopic and Index F58:158 has phenotypically non-affected parents, but she was diagnosed clini<br>revealed reduced photopic and very reduced scotopic (data not shown). Color p<br>marked pigmentary changes in the posterior pole and outside t |
|
|
|
| Index F58:I58 has phenotypically non-affected parents, but she was diagnosed clinically with RCD. ERG marked pigmentary changes in the posterior pole and outside the vascular arcades with marked vascular<br>attenuation and optic disc pallor (Figure 2a). Fluorescein angiography demonstrated diffuse granular<br>hyperfluorescence i marked pigmentary of the state number of the posterior pole with decreased fluorescence at the macula (Figure 2b).<br>Additionally, OCT scan of the patient exhibited diffuse thinning of the retinal layers (Figure 2c).<br>Genetic attenuation and optic disc pairs in the posterior angle paper and optical the macula (Figure 2b).<br>Additionally, OCT scan of the patient exhibited diffuse thinning of the retinal layers (Figure 2c).<br>Genetic findings<br>We dete

#### Genetic findings

my extracted the posterior pole with decrease in the estimate fluorescence in the mass (Figure 2c).<br>Additionally, OCT scan of the patient exhibited diffuse thinning of the retinal layers (Figure 2c).<br>Genetic findings<br>We de Genetic findings<br>We detected eight mutations in the ABCA4 gene in seven Lebanese families (Table 2). For inde<br>family 3, we found a mutation in the ABCA4 gene in heterozygosity state. However, the second<br>allele remains miss ( )<br>- f<br>ド Family 3, we found a mutations in the ABCA4 gene in seven Lebanese families (Trable 2). For index F3:I3 of family 3, we found a mutation in the ABCA4 gene in heterozygosity state. However, the second mutated allele remains Family 3, allele remains missing. The detected mono-allelic mutation is a missense mutation in exon 28 of<br>the ABCA4 gene: [M1]: c.4330G>C, p.(Trp1408Cys). M1 was not found in ExAC, gnomAD, or TopMed<br>populations; at the pro the *ABCA4* gene: [M1]: c.4330G>C, p.(Trp1408Cys). M1 was not found in ExAC, gnomAD, or TopMed<br>populations; at the protein level, it affects a conserved amino acid, Trp1408, with two exceptions. The<br>substitution was also p the ABCA4 generation, it affects a conserved amino acid, Trp1408, with two exceptions. The<br>substitution was also predicted to be damaging. Sanger sequencing validated the occurrence of M1 in a<br>heterozygous state in the pat substitution was also predicted to be damaging. Sanger sequencing validated the occurrence of M1 in a<br>heterozygous state in the patient F3:13 of this family (Figure S1 a). The mother was a heterozygous<br>carrier of M1, while substitution was also predicted to be damaging. Sanger sequencing validated the occurrence of M1, while the father carried the wild-type allele. M1 is novel and has not been reported before in literature databases. heterozygous state in the patient F3:I3 of this family (Figure S1 a). The mother was a heterozygous<br>carrier of M1, while the father carried the wild-type allele. M1 is novel and has not been reported<br>before in literature d carrier of M1, which we can also the factorization of M1 is not been reported the wild-type allegers are not been reported the wild-type allegers are not been reported to the wild-type allegers are not been reported to the

For Index F9:I9.1 of family 9, NGS revealed a compound heterozygous mutation in ABCA4; two missense mutations [M3] [17]: c.1936 and 13. According to population databases, M3 is a rare mutation<br>showing frequencies equal to 0.0006375, 0.0005517, and 0.00175 in ExAC, genomAD, and TOPMed<br>databases, respectively, and found ho p. (Vale)<br>showing frequencies equal to 0.0006375, 0.0005517, and 0.00175 in ExAC, genomAD, and TOPMed<br>databases, respectively, and found homozygous in several individuals in genomAD and TOPMed.<br>Referring to the UCSC genome databases, respectively, and found homozygous in several individuals in genomAD and TOPMed.<br>Referring to the UCSC genome browser, it has been observed that M3 mutation impacts an amino acid<br>residue (Ala192) that is conserv Referring to the UCSC genome browser, it has been observed that M3 mutation impacts an amino acid<br>residue (Ala192) that is conserved among multiple species, with the exception of four specific cases.<br>Furthermore, based on residue (Ala192) that is conserved among multiple species, with the exception of four specific cases.<br>Furthermore, based on PolyPhen-2 and MutationTaster algorithms, M3 is probably damaging and<br>disease-causing. In contrast Furthermore, based on PolyPhen-2 and MutationTaster algorithms, M3 is probably damaging and<br>disease-causing. In contrast, SIFT reported it as tolerated. On the other hand, the M4 mutation<br>appeared to be rare and homozygous Furthermore, and an entry thermore and multimerated on the other hand, the M4 mutation<br>appeared to be rare and homozygous in several individuals, as outlined in ExAC, GnomAD, and TOPMed<br>population databases with respective appeared to be rare and homozygous in several individuals, as outlined in ExAC, GnomAD, and TOPMed<br>population databases with respective frequencies of 0.001618, 0.001717, and 0.00554. M4 affects a<br>conserved amino acid (Val appeared to be reading to be reduced to b.001618, 0.001717, and 0.00554. M4 affects a conserved amino acid (Val643). Besides, based on the assessments of PolyPhen-2, SIFT, and MutationTaster, it was predicted that the M4 m conserved amino acid (Val643). Besides, based on the assessments of PolyPhen-2, SIFT, and<br>MutationTaster, it was predicted that the M4 mutation is probably damaging, damaging and disease-<br>causing, respectively. M3 [27-29] conserved amino acid (Valeta). Besides the anti-time accessions of PolyPhen-2, SiPT, and<br>MutationTaster, it was predicted that the M4 mutation is probably damaging, damaging and disease-<br>causing, respectively. M3 [27-29] a

 $ABCA4$  gene. This mutation is well-known in exon 42, [M5]: c.5882G>A; p.(Gly1961Glu), rs1800553. M5 mutations was verified by Sanger sequencing in F9:19.1. The father and the mother of family 9 were<br>heterozygous carriers of M4 and M3, respectively, confirming an adequate co-segregation (Figure S1 b).<br>The index of family heterozygous carriers of M4 and M3, respectively, confirming an adequate co-segregation (Figure S1 b).<br>The index of family 31, F31:I31, carries a homozygous missense mutation within exon 42 of the<br>ABCA4 gene. This mutation The index of family 31, F31:l31, carries a homozygous missense mutation within exon 42 of the<br>ABCA4 gene. This mutation is well-known in exon 42, [M5]: c.5882G>A; p.(Gly1961Glu), rs1800553. M5<br>exhibited a rare occurrence a ן<br>}}<br>}} The index of family 31, The index of the index of the index of a homocygous in some individual from ExAC, gnomAD, and TOPmed population databases (respective frequencies= 0.005054, 0.004564, and 0.00284). This mutation aff Resonant and the measure is the measure of the proposition is exongene. This mutation is a parameter and was observed to be homozygous in some individual from ExAC, gnomAD, and TOPmed population databases (respective frequ exhibited a rare occurrences and TOPmed population databases (respective frequencies= 0.005054, 0.004564, and<br>
0.00284). This mutation affects a conserved residue (Gly1961) in different species, except for one.<br>
Furthermor 0.00284). This mutation affects a conserved residue (Gly1961) in different species, except for one.<br>Furthermore, according to the predictions made by PolyPhen-2, SIFT, and MutationTaster, the M5<br>mutation was determined to Furthermore, according to the predictions made by PolyPhen-2, SIFT, and MutationTaster, the M5<br>mutation was determined to be probably damaging, damaging, and disease-causing respectively. Sanger<br>sequencing analysis validat Furthermore, according to the predictions made by PolyPhen-2, and, and mutations mutations made mutation was determined to be probably damaging, damaging, and disease-causing respectively. Sanger sequencing analysis valida

mutation analysis validated the presence of this homozygous mutation in F31:131 (Figure S1 c). The<br>father of the affected patient was deceased; however, the mother was found homozygous WT.<br>The index F37:137 of family 37 ha Father of the affected patient was deceased; however, the mother was found homozygous WT.<br>The index F37:I37 of family 37 had a homozygous nonsense mutation in the exon 44 of ABCA4. This<br>substitution mutation that resulted The index F37:137 of family 37 had a homozygous nonsense mutation in the exon 44 of AB<br>substitution mutation that resulted in the appearance of a stop codon is [M6]: c.<br>p.(Arg2030Ter), rs61751383. According to population d |
|
|
| The index F37:I383. According to population databases, M6 is a rare and heterozygous<br>p.(Arg2030Ter), rs61751383. According to population databases, M6 is a rare and heterozygous<br>mutation with frequencies equal to 0.0000247 substitution mutation mutation mutation mutation mutation with frequencies equal to 0.00002471, 0.00002784, and 0.00000756 in ExAC, genomAD and TOPMed, respectively, affecting a conserved amino acid with one exception base p. (Arg. 2030)<br>mutation with frequencies equal to 0.00002471, 0.00002784, and 0.00000756 in ExAC, genomAD and<br>TOPMed, respectively, affecting a conserved amino acid with one exception based on UCSC genome<br>g mutation with frequencies exception based on UCSC genome<br>general to 0.0002471, and 0.0002784, and 0.0000756<br>Frequencies exception based on UCSC genome<br>g TOPMed, respectively, affecting a conserved amino acid with one exception based on UCSC genome

browser. Furthermore, MC is predicted to be an encoded to be an entirely and among the disease of M6 (Figure S1 d). Referring to literature databases, M6 is not a novel mutation [32].<br>[32].<br>Index F41:141 presented a homozy

This mutation may cannote by Sanger sequencing in Factor Interactory process, Me is not a novel mutation<br>Theterozygous carriers of M6 (Figure S1 d). Referring to literature databases, M6 is not a novel mutation<br>The same fo heterozygous mutation [M7]: c.970T>C; p.(Cys324Arg) in exon 8. The parents<br>were heterozygous for M7 (Figure S1 e), which was extremely rare and absent in online databases.<br>Prediction tools revealed it as disease-causing. B .<br>Index<br>were<br>Predi<br>amin<br>repor |
|
|
|
| Independent and absent in online databases.<br>
Index F41: In the parameter and absent in online databases.<br>
Prediction tools revealed it as disease-causing. Based on the UCSC genome browser, the impacted<br>
In action accomposi Prediction tools revealed it as disease-causing. Based on the UCSC genome browser, the impacted<br>amino acid (Cys324) is conserved with two variations in two species. This mutation was previously<br>reported in a Chinese popula

Prediction to the security of an interact causing. There is an isome browser, this mutation was previously<br>reported in a Chinese population [33].<br>In family 56, F56:156 harbors a compound heterozygous mutation. The first is reported in a Chinese population [33].<br>In family 56, F56:156 harbors a compound heterozygous mutation. The first is the missense substitution<br>in exon 42 [M5], while the second is a nonsense mutation in exon 30 [M8]: c.4383 In family 56, F56:156 harbors a comport<br>in exon 42 [M5], while the second is a<br>affecting a highly conserved amino ac<br>shown in any population dataset, indi<br>disease-causing on MutationTaster and |
|
| a<br>| In exon 42 [M5], while the second is a nonsense mutation in exon 30 [M8]: c.4383G>A; p.(Trp1461Ter)<br>affecting a highly conserved amino acid. Notably, M8 was reported in the literature [34]. M8 was not<br>shown in any populati affecting a highly conserved amino acid. Notably, M8 was reported in the literature [34]. M8 was not<br>shown in any population dataset, indicating that it is extremely rare. Moreover, M8 was shown to be<br>disease-causing on Mu shown in any population dataset, indicating that it is extremely rare. Moreover, M8 was shown to be<br>disease-causing on MutationTaster and damaging on SIFT. Sanger sequencing validated the presence of<br>M5 and M8 in F56:156. disease-causing on MutationTaster and damaging on SIFT. Sanger sequencing validated the presence of<br>M5 and M8 in F56:156. Besides, it revealed that the disease co-segregated within the family, where the<br>father was found he

M5 and M8 in F56:156. Besides, it revealed that the disease co-segregated within the family, where the<br>father was found heterozygous for M8 and the mother was heterozygous for M5 (Figure S1 f).<br>Mutational analysis in index Father was found heterozygous for M8 and the mother was heterozygous for M5 (Figure S1 f).<br>Mutational analysis in index F58:I58 revealed a homozygous missense mutation [M9] in exon 22. M9:<br>c.3259G>A; p.(Glu1087Lys), rs6175 matrical analysis in index F58:158 revealed a homozygous missense mutation [M9] in exones.<br>C.3259G>A; p.(Glu1087Lys), rs61751398 is rare and never homozygous with an allele fre<br>0.00003296 in ExAC, 0.00001193 in genomAD and |
|
|} C.3259G>A; p.(Glu1087Lys), rs61751398 is rare and never homozygous with an allele frequency of<br>0.00003296 in ExAC, 0.00001193 in genomAD and 0.0000227 in TOPMed. M9 is likely damaging on<br>PolyPhen-2, damaging on SIFT, and d C.00003296 in ExAC, 0.00001193 in genomAD and 0.0000227 in TOPMed. M9 is likely damaging on<br>PolyPhen-2, damaging on SIFT, and disease-causing on MutationTaster. The affected amino acid<br>(Gly1087) is also highly conserved, a PolyPhen-2, damaging on SIFT, and disease-causing on MutationTaster. The affected amino acid (Gly1087) is also highly conserved, as found in the UCSC genome browser. The zygosity of the M9 mutation was verified through San (Gly1087) is also highly conserved, as found in the UCSC genome browser. The zygosity of the M9 mutation was verified through Sanger sequencing in the index patient. In contrast, M9 was heterozygous in the mother (Figure (Glynn) was verified through Sanger sequencing in the index patient. In contrast, M9 was heterozygous in the mother (Figure S1 g). This finding confirms the co-segregation of the mutation with the disease. The literature heterozygous in the mother (Figure S1 g). This finding confirms the co-segregation of the mutation with<br>the disease. The literature search showed M9 as a known variation [32]. the disease. The literature search showed M9 as a known variation [32]. the disease. The literature search showed M9 as a known variation [32].

#### **Discussion**

mutations underlying IRDs of different severity and manifestations [11]. We found eight mutations in<br>the ABCA4 gene in a small Lebanese group, seven of which had been identified before in different<br>populations, and one is the *ABCA4* gene in a small Lebanese group, seven of which had been identified before in different<br>populations, and one is novel, [M1]; c.4330G>C; p.(Trp1408Cys). The eight identified mutations were<br>associated with varying

populations, and one is novel, [M1]; c.4330G>C; p.(Trp1408Cys). The eight identified mutations were<br>associated with varying forms of IRDs. Sanger sequencing verified all putatively pathogenic mutations,<br>revealing their coassociated with varying forms of IRDs. Sanger sequencing verified all putatively pathogenic mutations,<br>revealing their co-segregation with the associated phenotypes.<br>ABCA4 is localized in 1p21–p22.1 on chromosome 1, consis associated with varying forms of IRDs. Interesting contractor in putation, providing their co-segregation with the associated phenotypes.<br>ABCA4 is localized in 1p21-p22.1 on chromosome 1, consisting of 50 exons that encode RECA4 is localized in 1p21-p22.1 on chromosome 1, consisting<br>ATP-binding cassette transporter protein of 2,273 amino acid<br>situated at the outer segments of rod and cone photoreceptor<br>retinal and toxic substances from the d ノノミ にん ATP-binding cassette transporter protein of 2,273 amino acids with a molecular weight of ~250 kDa<br>situated at the outer segments of rod and cone photoreceptors [9, 35]. ABCA4 protein moves all trans-<br>retinal and toxic sub Situated at the outer segments of rod and cone photoreceptors [9, 35]. ABCA4 protein moves all trans-<br>retinal and toxic substances from the disc lumen to the photoreceptors' cytoplasm. These by-products<br>are transported to retinal and toxic substances from the disc lumen to the photoreceptors' cytoplasm. These by-products<br>are transported to the retinal pigment epithelium (RPE) [36]. The association of bi-allelic mutations in<br>ABCA4 with diffe

Determining the biallelic mutations may be challenging due to the ABCA4's large size, the wide range of ABCA4 with different forms of IRDS comprises a loss-of-function component and photoreceptor stress<br>due to faulty localization and folding of protein [35].<br>Determining the biallelic mutations may be challenging due to the A due to faulty localization and folding of protein [35].<br>Determining the biallelic mutations may be challenging due to the *ABCA4's* large size, the wide range of<br>pathogenic variations it exhibits such as hypomorphic mutati Determining the biallelic mutations may be challeng<br>pathogenic variations it exhibits such as hypomorp<br>and lately, deep-intronic mutations [37]. In line with<br>patient in family 3 revealed only one mutant allel<br>rendering the [<br>|}<br>|}<br>|} Determining the biallelic mutations may be challenging due to the *ABCA4*'s large size, the wide range of pathogenic variations it exhibits such as hypomorphic mutations, non-canonical splice site mutations, and lately, de pathogenic variations in antitions [37]. In line with previous literature [38], targeted sequencing of the patient in family 3 revealed only one mutant allele, while the second mutation is still missing, thus rendering the patient in family 3 revealed only one mutant allele, while the second mutation is still missing, thus<br>rendering the case of family 3 genetically unsolved. According to Nassisi et al., there are two basic<br>explanations for t patient in family 3 genetically unsolved. According to Nassisi et al., there are two basic<br>explanations for this performance's relative poorness: (1) because the whole gene was not scanned, the<br>second allele may be located rendering the case of family 3 generative process: (1) because the whole gene was not scanned, the<br>second allele may be located in the gene's promoter, untranslated regions (UTRs), or another deep<br>intronic region. Addition explanations for this performance's relative poorness: (1) because the whole gene was not scanned, the<br>second allele may be located in the gene's promoter, untranslated regions (UTRs), or another deep<br>intronic region. Addi second allele may be located in the gene's promoter, untranslated regions (UTRs), or another deep<br>intronic region. Additionally, the phenotype may be caused by unrecognized copy number variations<br>(CNVs) in exonic or intron interestigate of the patient of the phenocopies associated with STGD, it may be necessary to examine<br>case [37]. (2) As there are multiple phenocopies associated with STGD, it may be necessary to examine<br>the exome or genome (CNVs) in example provides associated with STGD, it may be necessary to examine<br>the exome or genome of the patient to identify the existence of pathogenic mutations in other genes,<br>possibly additional genes not previously case the exome or genome of the patient to identify the existence of pathogenic mutations in other genes,<br>possibly additional genes not previously linked with IRDs [37].<br>The ABCA4 locus provides insight into a multitude of

the exome or genome or genome or previously linked with IRDs [37].<br>The ABCA4 locus provides insight into a multitude of founder alleles in a particular geographical region.<br>What makes the ABCA4 locus particularly intriguin possibly additional generatopy online, minimized with IRDs.<br>The ABCA4 locus provides insight into a multitude of founder<br>What makes the ABCA4 locus particularly intriguing is; (1)  $\begin{bmatrix} 1 \\ 1 \end{bmatrix}$ What makes the ABCA4 locus particularly intriguing is; (1) almost every population has its intrinsic  $11$  $W_{\text{max}}$  locus particularly intriguing is; (1) almost every population has its intrinsic.

mutations, (2) the most prevalent disease-causing mutation in the *ABCA4* gene, namely c.5882G>A;<br>p. (Gly1961Glu), exhibits a likely origin in Eastern Africa, with frequencies ranging from approximately 8%<br>to 10% in popula ethnic origins [11]. The most previous tend of the most prevalent distributed in popposimately 8% to 10% in populations hailing from Somalia, Kenya, and Ethiopia. [11, 40]. The dispersal of c.5882G>A;<br>p. (Gly1961Glu) world p.(Gly1961Glu) worldwide can be attributed to the migratory movement of populations across different<br>p.(Gly1961Glu) worldwide can be attributed to the migratory movement of populations across different<br>regions. Yet, the al to 10% p. (Gly1961Glu) worldwide can be attributed to the migratory movement of populations across different<br>regions. Yet, the allele frequency has declined substantially with evolution, reaching about 0.4% in<br>European nat

programs. Yet, the allele frequency has declined substantially with evolution, reaching about 0.4% in<br>European nations, implying that the variation is causative across almost all populations [11].<br>Herein, we report the fir European nations, implying that the variation is causative across almost all populations [11].<br>Herein, we report the first detection of the mutation c.5882G>A p.(Gly1961Glu) in the Lebanese<br>population. The presence of the European nations, implying that the variables can<br>determine in perfections. The presence of the Gly1961Glu allele (homozygous or compound heter<br>associated with markedly different phenotypes [11]. In this study, Gly1961Glu ト ミニート population. The presence of the Gly1961Glu allele (homozygous or compound heterozygous) is<br>associated with markedly different phenotypes [11]. In this study, Gly1961Glu was detected in about<br>30% of our group (2 patients ou populated with markedly different phenotypes [11]. In this study, Gly1961Glu was detected in about<br>30% of our group (2 patients out of 7) in both homozygosity and compound heterozygosity states.<br>Mutational analysis reveale associated with markedly and test phenotypes [11]. In this study, experience into acternational analysis revealed p. Gly1961Glu in a homozygous state in the index of family 31 diagnosed with RCD, while it was in compound h 30% of our group (2 patients out of 7) in a term in the group of the index of family 31 diagnosed<br>with RCD, while it was in compound heterozygous state along with c.4383G>A; p.(Trp1461Ter) in the<br>patient of family 56. Init with RCD, while it was in compound heterozygous state along with c.4383G>A; p.(Trp1461Ter) in the<br>patient of family 56. Initially, it was thought that Gly1961Glu was not likely to be pathogenic, mainly<br>when found in the ho patient of family 56. Initially, it was thought that Gly1961Glu was not likely to be pathogenic, mainly<br>when found in the homozygous state [41]. A homozygous c.5882G>A; p.(Gly1961Glu) mutation was<br>described in an asymptoma when found in the homozygous state [41]. A homozygous c.5882G>A; p.(Gly1961Glu) mutation was<br>described in an asymptomatic 25 years old Somali male with normal vision assessment [40, 41].<br>However, this was justified by a st described in an asymptomatic 25 years old Somali male with normal vision assessment [40, 41].<br>However, this was justified by a study in which patients homozygous for c.5882G>A; p.(Gly1961Glu)<br>were reported to have later di However, this was justified by a study in which patients homozygous for c.5882G>A; p.(Gly1961Glu)<br>were reported to have later disease onset (>25 years old) than would be seen in STGD in typical cases<br>[40]. Hence, it is lik However reported to have later disease onset (>25 years old) than would be seen in STGD in typical cases<br>[40]. Hence, it is likely to find an individual with normal vision assessment at 25 but may develop<br>symptoms in later [40]. Hence, it is likely to find an individual with normal vision assessment at 25 but may develop<br>symptoms in later life stages [40]. A prior investigation found an association between the c.5882G>A;<br>p.(Gly1961Glu) muta symptoms in later life stages [40]. A prior investigation found an association between the c.5882G>A;<br>p.(Gly1961Glu) mutation, with the development of bull's eye maculopathy and early disruption of<br>central photoreceptors, p. (Gly1961Glu) mutation, with the development of bull's eye maculopathy and early disruption of<br>central photoreceptors, supporting the notion that this mutant allele has a disease-causing effect [42].<br>The missense mutatio p.(Gly1961Glu) mutation, with the development of bull's eye maculopathy and early disruption of<br>central photoreceptors, supporting the notion that this mutant allele has a disease-causing effect [42].<br>The missense mutation The missense mutation allele c.5882G>A; p.(Gly1961Glu) has been observed to be linked with retinal<br>impairment that is localized to the macula, without being widespread [42]. This glycine-to-glutamine<br>substitution mutation Impairment that is localized to the macula, without being widespread [42]. This glycine-to-glutamine<br>substitution mutation in exon 42 was envisioned to be outside the functional domains of ABCA4 [43].<br>c.5882G>A; p.(Gly1961 substitution mutation in exon 42 was envisioned to be outside the functional domains of ABCA4 [43].<br>c.5882G>A; p.(Gly1961Glu) is expected to affect protein function by reducing ATP binding and ATPase<br>activity, as shown by c.5882G>A; p.(Gly1961Glu) is expected to affect protein function by reducing ATP binding and ATPase<br>activity, as shown by indirect functional testing [44, 45]. Generally, c.5882G>A; p.(Gly1961Glu) was<br>reported to be cause activity, as shown by indirect functional testing [44, 45]. Generally, c.5882G>A; p.(Gly1961Glu) was<br>reported to be cause milder phenotypes. However, it may associate with phenotypes of varying severity<br>[42]. Its actual cl reported to be cause milder phenotypes. However, it may associate with phenotypes of varying severity [42]. Its actual clinical manifestation may rely on the severity of the other paired mutant allele, as revealed by previ [42]. Its actual clinical manifestation may rely on the severity of the other paired mutant allele, as<br>revealed by previous genotype-phenotype investigations [42, 46]. Hence, the type of the<br>combined ABCA4 mutant alleles revealed by previous genotype-phenotype investigations [42, 46]. Hence, the type of the combined ABCA4 mutant alleles in compound heterozygosity determines the phenotype severity,<br>12 combined ABCA4 mutant alleles in compound heterozygosity determines the phenotype severity,<br>12 combined ABCA4 mutant alleles in compound the phenotype severity,  $\frac{1}{2}$ 

external environmental factors that are still unknown [42, 43]. Our index F31:l31 demonstrated a RCD<br>disease pattern, similar to what Burke et al. reported in a Somali patient with a homozygous<br>p.Gly1961Glu mutation, showi external environmental factors that are still unitarity (e.g., e.g.) of and a Somali patient with a homozygous<br>p.Gly1961Glu mutation, showing the diversity of phenotypes caused by ABCA4 mutations [40].<br>Interestingly, Burke p. Gly1961Glu mutation, showing the diversity of phenotypes caused by ABCA4 mutations [40].<br>Interestingly, Burke et al. have examined 12 individuals with homozygous p. Gly1961Glu and found that<br>all of them have ABCA4 retin

p. Therestingly, Burke et al. have examined 12 individuals with homozygous p.Gly1961Glu and found that<br>all of them have *ABCA4* retinopathies, with severe phenotypes consistent with the existence of<br>additional (modifier) Interestingly, Burke et al. have entimated to interest and interesting prespect provided into the existence of<br>In dividual (modifier) ABCA4 mutations [40].<br>In family 56, the mutation M8: c.4383G>A; p.(Trp1461Ter) found wit additional (modifier) *ABCA4* mutations [40].<br>
In family 56, the mutation M8: c.4383G>A; p.(Trp1461Ter) found with p.(Gly1961Glu) was confirmed<br>
through co-segregation analyses: the index presented it in a compound heteroz In family 56, the mutation M8: c.4383G>A;<br>through co-segregation analyses: the index<br>unaffected parents, F56:M56 and F56:F56, w<br>finding provides confirmation of the autosor<br>mutation was found before along with anoth<br>M3: c. ו<br>ז<br>ז In family 1991. The mutation co-segregation analyses: the index presented it in a compound heterozygous state, while the<br>unaffected parents, F56:M56 and F56:F56, were heterozygous carriers of M5 and M8, respectively. This<br> unaffected parents, F56:M56 and F56:F56, were heterozygous carriers of M5 and M8, respectively. This<br>finding provides confirmation of the autosomal recessive inheritance pattern observed in F56:I56. This<br>mutation was found

manizon paramigram in the autosomal recessive inheritance pattern observed in F56:156. This<br>finding provides confirmation of the autosomal recessive inheritance pattern observed in F56:156. This<br>mutation was found before a mutation was found before along with another allele in a patient diagnosed with CRD [34].<br>M3: c.574G>A; p.(Ala192Thr) and M4: c.1927G>A; p.(Val643Met) detected by NGS in patient F9:I9.1 of<br>family 9 as compound heterozygous mutation was found before all the mutation was found that in a matism of the standing of as compound heterozygous were further confirmed by Sanger sequencing. This<br>diagnosed with CRD. Co-segregation analysis was establishe r<br>f<br>c<br>i<br>t Mamily 9 as compound heterozygous were further confirmed by Sanger sequencing. This patient was<br>diagnosed with CRD. Co-segregation analysis was established where M3 and M4 were affirmed by<br>Sanger sequencing in the mother a family 9 as composed with CRD. Co-segregation analysis was established where M3 and M4 were affirmed by<br>Sanger sequencing in the mother and the father, respectively, validating the autosomal recessive<br>inheritance fashion o Sanger sequencing in the mother and the father, respectively, validating the autosomal recessive<br>inheritance fashion of CRD in F9:19.1. Consistent with our results, M3: c.574G>A causing alanine to<br>threonine p.(Ala192Thr) s Sanger sequencing in the motion and the father, respectively, remaining the antiexant recession in<br>inheritance fashion of CRD in F9:19.1. Consistent with our results, M3: c.574G>A causing alanine to<br>threonine p.(Ala192Thr) Inheritance fashion of CRD is a strategistic factor of the CRD in a subject with CRD [27].<br>
Moreover, Webster et al. have also found this mutation in an individual clinically diagnosed with STGD<br>
[48]. Both CRD and STGD ha Moreover, Webster et al. have also found this mutation in an individual clinically diagnosed with STGD<br>[48]. Both CRD and STGD have clinical features in common, such as age of onset, macula involvement,<br>and a progressive d The 148]. Both CRD and STGD have clinical features in common, such as age of onset, macula involvement,<br>and a progressive decline in visual acuity while retaining relatively preserved night vision [27]. However,<br>unlike STG and a progressive decline in visual acuity while retaining relatively preserved night vision [27]. However, unlike STGD, which is restricted to the posterior pole, CRD generally affects the whole retina [27]. The observati and a progressive decline in visual acuity manchestance, preserved in governed progressive (27]. The observation of such a common mutation between CRD and STGD shows overlapping between these two disorders [27]. STGD patie unlike STGD shows overlapping between these two<br>disorders [27]. STGD patients can develop substantial, widespread pigmentary degenerative<br>impairments that are comparable to those seen in CRD patients [27]. Additionally, th disorders [27]. STGD patients can develop substantial, widespread pigmentary degenerative<br>impairments that are comparable to those seen in CRD patients [27]. Additionally, the other mutation<br>M4: c.1927G>A; p.(Val643Met) ha impairments that are comparable to those seen in CRD patients [27]. Additionally, the other mutation<br>M4: c.1927G>A; p.(Val643Met) has also been reported previously by Briggs et al. as a heterozygous<br>mutation with another a impair in the c.1927G>A; p.(Val643Met) has also been reported previously by Briggs et al. as a heterozygous<br>mutation with another allele and found to cause STGD [30]. Maugeri et al. have suggested a genotype-<br>phenotype cor MHTHELT BEA; p.(Fincentry the line of severic previously between the American, by Bridge and Theorem and Theorem multion with another allele and found to cause STGD [30]. Maugeri et al. have suggested a genotype-<br>phenotype phenotivity and the level of severity of the IRD [49]. According to this model, compound heterozygosity for<br>two severe (null) *ABCA4* mutations cause RCD, the most severe phenotype [49]. Whereas, in case of<br>13 two severe (null)  $ABCA4$  mutations cause RCD, the most severe phenotype [49]. Whereas, in case of 13  $t_{\text{max}}$  (null) ABCA4 mutations cause  $\frac{1}{2}$  mutations cause  $\frac{1}{2}$ . Whereas, in case of  $\frac{1}{2}$ 

partial retention of ABCA4 mutation, while STGD macular degeneration will appear if a severe mutation is<br>inherited along with a mild *ABCA4* mutation [49].<br>Family 37 presented a consanguinity case with a child diagnosed wi moderately severe mutation, mine streshmental degeneration into appear in a severe mutation is<br>inherited along with a mild ABCA4 mutation [49].<br>Family 37 presented a consanguinity case with a child diagnosed with CRD. The Family 37 presented a consanguinity case with a<br>mutation revealed in the index of family 37, M7: d<br>destabilize the messenger RNA by the nonsens<br>expressed because the affected arginine residue<br>binding domain of ABCA4 protei F<br>r<br>c<br>c Family 37, M7: c.6088C>T, causing a stop codon at Arg2030, is likely to<br>mutation revealed in the index of family 37, M7: c.6088C>T, causing a stop codon at Arg2030, is likely to<br>destabilize the messenger RNA by the nonsens destabilize the messenger RNA by the nonsense-mediated decay mechanism in case the protein is<br>expressed because the affected arginine residue at position 2030 is situated in the second nucleotide-<br>binding domain of ABCA4 p expressed because the affected arginine residue at position 2030 is situated in the second nucleotide-<br>binding domain of ABCA4 protein [50, 51]. This mutation has been identified before in heterozygous and<br>compound heteroz [33]. Similarly, a homozygous missense mutation in exon 22 of  $ABCA4$ : c.3259G>A; p.(Glu1087Lys) was binding domain of ABCA4 proteins and associated with STGD or CRD [43, 52, 53]. The patient of family 41,<br>F41:141, whose parents were relatives, was diagnosed with CRD and was shown to harbor the<br>homozygous missense mutatio F41:141, whose parents were relatives, was diagnosed with CRD and was shown to harbor the<br>homozygous missense mutation c.970T>C; p.(Cys324Arg). Interestingly, this mutation was only seen<br>once in a compound heterozygous st F41:I41, MELE parameter relatives, was angles to hard the late the metric menter in the metric of the homozygous missense mutation c.4316G>T; p.(Gly1439Val) in a Chinese patient with STGD [33]. Similarly, a homozygous miss homozygous missense mutation in example. The USANG and Mathematical and the USA once in a compound heterozygous state with c.4316G>T; p.(Gly1439Val) in a Chinese patient with STGD<br>[33]. Similarly, a homozygous missense mut once in a compound heterozygous missense mutation in exon 22 of *ABCA4*: c.3259G>A; p.(Glu1087Lys) was<br>associated with RCD in the index patient of family 58. This mutation was previously found in the<br>compound heterozygous

Exercised with RCD in the index patient of family 58. This mutation was previously found in the<br>compound heterozygous state associated with STGD and CRD [54, 55].<br>In conclusion, eight mutations in the ABCA4 gene were detec compound heterozygous state associated with STGD and CRD [54, 55].<br>In conclusion, eight mutations in the ABCA4 gene were detected in seven Lebanese patients diagnosed<br>with different forms of related retinopathies. One muta In conclusion, eight mutations in the ABCA4 gene were detected in se<br>with different forms of related retinopathies. One mutation turned o<br>p.(Trp1408Cys). When Combined with the phenotypic data, our fin<br>heterogeneity of the |
|
|}<br>| נ In contribution, eight mutation in the ABCA4 gene interaction turned out to be novel; [M1]; c.4330G>C;<br>p.(Trp1408Cys). When Combined with the phenotypic data, our findings show the significant allelic<br>heterogeneity of the p.(Trp1408Cys). When Combined with the phenotypic data, our findings show the significant allelic<br>heterogeneity of *the ABCA4* gene. The expanded capabilities of genetic screening, assisted by the<br>utilization of high-resol p. The terogeneity of the ABCA4 gene. The expanded capabilities of genetic screening, assisted by the utilization of high-resolution diagnostic imaging technologies, have enlarged the phenotypic expression spectrum of ABCA utilization of high-resolution diagnostic imaging technologies, have enlarged the phenotypic expression<br>spectrum of *ABCA4-associated* diseases. A thorough understanding of the *ABCA4* mutations and its<br>correlations with t spectrum of *ABCA4-associated* diseases. A thorough understanding of the *ABCA4* mutations and its correlations with the phenotype are indispensable to comprehend its association with different forms of IRDs. spectrum of ABCA4-association of ABCA4-association of the ABCA4-association with different forms of IRDs.<br>IRDs. correlations with the phenotype are indispensable to comprehend its association with different forms of  $\alpha$  association with different forms of  $\alpha$  association with different forms of  $\alpha$  association with different form

### Acknowledgments

Merticipating in this study. Additionally, we extend our appreciation to 3billion® (Seoul, Korea) for<br>generously providing free whole-exome sequencing to the index patients F37:137 and F56:156.<br>Author Contributions<br>SES fra

## Author Contributions

generously providing free whole-exome sequencing to the index patients F37:137 and F56:156.<br>
Author Contributions<br>
SES framed the methodology. AA, CH, and SES conducted the formal analysis. LJ, SES, HA, and MI, LJ and<br>
SES Author Contributions<br>SES framed the methodology. AA, CH, and SES conducted the formal analysis. LJ, SES, HA, and<br>SES investigated. AA, CH, and LJ collected resources. MI and LJ wrote the original draft prepar<br>wrote the rev ノミート SES investigated. AA, CH, and LJ collected resources. MI and LJ wrote the original draft preparation. SES<br>wrote the review and editing. SES administered the project. AA and SES funded the acquisition.<br>Data Availability<br>All SES investigated. Any only and LI content resources in the LI and DI and Dignitically preparation.<br>Wrote the review and editing. SES administered the project. AA and SES funded the acquisition.<br>Data Availability<br>All our da

# $\begin{array}{c} 1 \\ 1 \\ 2 \end{array}$ Data Availability

Data Availability<br>All our data is shared in the manuscript and the supplementary Figure.<br>Confidentiality<br>The patient and the family IDs are not known to anyone outside the PI: SES.

# $\frac{1}{\sqrt{2}}$ Confidentiality

Confidentiality<br>The patient and the family IDs are not known to anyone outside the PI:<br>The patient and the family IDs are not known to anyone outside the PI: The patient and the family IDs are not known to anyone outside the PI: SES.

## References

- 
- 
- 1. Front Cell Dev Biol, 2021. 9: p. 645600.<br>
2. Liu, X., et al., Molecular diagnosis based on comprehensive genetic testing in 800 Chinese<br>
families with non-syndromic inherited retinal dystrophies. Clin Exp Ophthalmol, 20 Front Cell Dev Biol, 2021. 3: p. 043600.<br>Liu, X., et al., *Molecular diagnosis based<br>families with non-syndromic inherited re*<br>46-59.<br>Perea-Romero, I., et al., *Genetic landsco<br>Spain and their therapeutic and extende*<br>11(1 Families with non-syndromic inherited retinal dystrophies. Clin Exp Ophthalmol, 2021. 49(<br>
46-59.<br>
Perea-Romero, I., et al., *Genetic landscape of 6089 inherited retinal dystrophies affected of*<br>
Spain and their therapeuti Families with non-syndromic inherited retinal dystrophies. Clin Exp Ophthalmol, 2021: 49(1): p.<br>Perea-Romero, I., et al., Genetic landscape of 6089 inherited retinal dystrophies affected cases<br>Spain and their therapeutic a Perea-l<br>S*pain a*<br>S*pain a*<br>11(1): IChen, 1<br>*Taiwan*<br>Salmar<br>pigmer<br>Gill, J.S Spain and their therapeutic and extended epidemiological implications. Scientific Reports, 2021.<br>
11(1): p. 1526.<br>
Chen, T.-C., et al., Genetic characteristics and epidemiology of inherited retinal degeneration in<br>
Taiwan.
- 11(1): p. 1526.<br>Chen, T.-C., et al., *Genetic characteristics and epidemiology of inherited retinal degeneration in*<br>Taiwan. npj Genomic Medicine, 2021. 6(1): p. 16.<br>Salmaninejad, A., et al., *Next-generation sequencing an* **11(1): p. 1526.**<br>Chen, T.-C., et a<br>*Taiwan.* npj Ge<br>Salmaninejad, *l*<br>pigmentosa. O<sub>l</sub><br>Gill, J.S., et al., and prospects f<br>Birtel, J., et al.,<br>cone/cone-rod<br>Tanna, P., et al.
- 
- Form in the all the arguments of ABCA4 and Its Role in the Visual Cycle and prospects for therapy. Br J Ophthalmol, 2019. 103(5): p. 711-20.<br>
Sill, J.S., et al., Progressive cone and cone-rod dystrophies: clinical features
- 
- Falmaninejad, A., et al., *Next-generation sequenci*<br>pigmentosa. Ophthalmic Genet, 2019. 40(5): p. 39<br>Gill, J.S., et al., *Progressive cone and cone-rod dyst*<br>and prospects for therapy. Br J Ophthalmol, 2019.<br>Birtel, J., e pigmentosa. Ophthalmic Genet, 2013. 40(5): p. 333-402.<br>Gill, J.S., et al., *Progressive cone and cone-rod dystrophies*<br>and prospects for therapy. Br J Ophthalmol, 2019. **103**(5)<br>Birtel, J., et al., *Clinical and genetic ch*
- Taiwan. npj Genomic Medicine, 2021. 6(1): p. 16.<br>
5. Salmaninejad, A., et al., Next-generation sequencing and its application in diagnosis of retinitis<br>
pigmentosa. Ophthalmic Genet, 2019. 40(5): p. 393-402.<br>
6. Gill, J.S
- 
- and prospects for therapy. Br J Ophthalmol, 2019. 103(5): p. 711-20.<br>
7. Birtel, J., et al., *Clinical and genetic characteristics of 251 consecutive patients with macular and*<br> *cone/cone-rod dystrophy.* Sci Rep, 2018. **8** and prospects for therapy. Br 3 Ophthalmol, 2019. 103(5): p. 711-20.<br>Birtel, J., et al., *Clinical and genetic characteristics of 251 consecutive*<br>cone/cone-rod dystrophy. Sci Rep, 2018. **8(1)**: p. 4824.<br>Tanna, P., et al., *Cone-rod dystrophy.* Sci Rep, 2018. **8(1)**: p. 4824.<br> **8.** Tanna, P., et al., Stargardt disease: clinical features, molecular genetics, animal models and<br> *therapeutic options.* Br J Ophthalmol, 2017. **101**(1): p. 25-30.<br> cone/cone-rod dystrophy. Sci Rep, 2018. 8(1): p. 4824.<br>Tanna, P., et al., *Stargardt disease: clinical features, matherapeutic options.* Br J Ophthalmol, 2017. **101**(1): p. *i*<br>Molday, R.S., *Insights into the Molecular Pr* therapeutic options. Br J Ophthalmol, 2017. **101**(1): p. 25-30.<br>
9. Molday, R.S., Insights into the Molecular Properties of ABCA4 and Its Role in the Visual Cycle<br>
Stargardt Disease. Prog Mol Biol Transl Sci, 2015. **134**: Encrupeutic options. Br 3 Ophthalmol, 2017. 101(1): p. 25-30.<br>
Molday, R.S., Insights into the Molecular Properties of ABCA4<br>
Stargardt Disease. Prog Mol Biol Transl Sci, 2015. 134: p. 415-<br>
Koenekoop, R.K., The gene for S Stargardt Disease. Prog Mol Biol Transl Sci, 2015. 134: p. 415-31.<br>
10. Koenekoop, R.K., *The gene for Stargardt disease, ABCA4, is a major retinal gene: a mini-review.*<br>
0phthalmic Genet, 2003. 24(2): p. 75-80.<br>
11. Creme Stargardt Disease. Frog Mol Biol Transl Sci, 2013. 134: p. 415-51.<br>Koenekoop, R.K., *The gene for Stargardt disease, ABCA4, is a majo*<br>Ophthalmic Genet, 2003. 24(2): p. 75-80.<br>Cremers, F.P.M., et al., *Clinical spectrum, g* Ophthalmic Genet, 2003. 24(2): p. 75-80.<br>Cremers, F.P.M., et al., *Clinical spectrum,*<br>retinal disease caused by ABCA4 mutation<br>100861.<br>Zernant, J., et al., *Analysis of the ABCA4 g*.<br>Vis Sci, 2011. **52**(11): p. 8479-87.<br>F
- 
- 
- 10. Koenekoop, R.K., The gene for Stargardt disease, ABCA4, is a major retinal gene: a mini-review. retinal disease caused by ABCA4 mutations. Progress in Retinal and Eye Research, 2020. 79: p. 100861.<br>
12. Zernant, J., et al., Analysis of the ABCA4 gene by next-generation sequencing. Invest Ophthalm Vis Sci, 2011. 52(1 retinal disease caused by ABCA4 mutations. Progress in Retinal and Eye Research, 2020: 79: p.<br>200861.<br>Zernant, J., et al., *Analysis of the ABCA4 gene by next-generation sequencing.* Invest Ophthalm<br>Vis Sci, 2011. 52(11): -<br>Zernant,<br>Vis Sci, 2<br>Fujinami<br>Invest Op<br>Boulange<br>*Underlyii*<br>20(19).<br>Smirnov,<br>*CLN3 Pat* Vis Sci, 2011. 52(11): p. 8479-87.<br>
13. Fujinami, K., et al., ABCA4 gene screening by next-generation sequencing in a British cohort.<br>
Invest Ophthalmol Vis Sci, 2013. 54(10): p. 6662-74.<br>
14. Boulanger-Scemama, E., et al. Vis Sci, 2011. 32(11): p. 6479-87.<br>Fujinami, K., et al., *ABCA4 gene selnvest Ophthalmol Vis Sci, 2013. 1*<br>Boulanger-Scemama, E., et al., *Ph.<br>Underlying Genetic Defects: Appli*<br>20(19).<br>Smirnov, V.M., et al., *Retinal Phe.* Invest Ophthalmol Vis Sci, 2013. 54(10): p. 6662-74.<br>
14. Boulanger-Scemama, E., et al., *Phenotype Analysis of Retinal Dystrophies in Light of the*<br>
14. Underlying Genetic Defects: Application to Cone and Cone-Rod Dystrop Invest Ophthalmol Vis Sci, 2013. 34(10): p. 6662-74.<br>Boulanger-Scemama, E., et al., *Phenotype Analysis of*<br>*Dnderlying Genetic Defects: Application to Cone and*<br>**20**(19).<br>Smirnov, V.M., et al., *Retinal Phenotype of Patie*
- Underlying Genetic Defects: Application to Cone and Cone-Rod Dystrophies. Int J Mol Sci<br>
20(19).<br>
15. Smirnov, V.M., et al., Retinal Phenotype of Patients With Isolated Retinal Degeneration<br>
16. CLN3 Pathogenic Variants in 20(19).<br>
Smirnov, V.M., et al., *Retinal Phenotype of Patients With Isolated Retinal Degeneration Due to*<br>
CLN3 Pathogenic Variants in a French Retinitis Pigmentosa Cohort. JAMA Ophthalmol, 2021.<br>
139(3): p. 278-291.<br>
Nash 20(19).<br>Smirnov<br>*CLN3 Pc*<br>**139**(3):<br>Nash, B<br>*therapy*<br>Jaffal, L.<br>Karczew<br>*K*arczew
- 139(3): p. 278-291.<br>Nash, B.M., et al., *R*<br>*therapy.* Transl Pedi<br>Jaffal, L., et al., *Nove<br>Lebanese Patients.* (<br>Karczewski, K.J., et al., *Th*<br>Fl Shamieh, S., et al.<br>*Thel Shamieh, S., et al.*<br>*relatively common d*
- 
- 
- 
- CLN3 Pathogenic Variants in a French Retinitis Pigmentosa Cohort. JAMA Ophthalmol, 2021.<br>
139(3): p. 278-291.<br>
16. Nash, B.M., et al., *Retinal dystrophies, genomic applications in diagnosis and prospects for*<br>
therapy. T 139(3): p. 278-291.<br>
Nash, B.M., et al., *Retinal dystrophies, genomic applications in diagnosis and prospects for*<br> *therapy*. Transl Pediatr, 2015. 4(2): p. 139-63.<br>
Jaffal, L., et al., *Novel Missense Mutations in BEST1* 16. Instanting the may applicate the may be therapy. Transl Pediatr, 2015. 4(2): p. 139-63.<br>
16. Institute Lebanese Patients. Genes (Basel), 2019. 10(2).<br>
18. Karczewski, K.J., et al., The mutational constraint spectrum qu therapy. Hansi Pediatr, 2013: 4(2): p. 139-63.<br>Jaffal, L., et al., *Novel Missense Mutations in B*<br>Lebanese Patients. Genes (Basel), 2019. **10**(2).<br>Karczewski, K.J., et al., *The mutational constra<br>humans. Nature, 2020.* Lebanese Patients. Genes (Basel), 2019. **10**(2).<br>
18. Karczewski, K.J., et al., *The mutational constraint spectrum quantified from variation in 141,45*<br>
humans. Nature, 2020. **581**(7809): p. 434-443.<br>
19. Kent, W.J., et a Lebanese Patients. Genes (Basel), 2019. 10(2).<br>Karczewski, K.J., et al., *The mutational constrationals.* Nature, 2020. **581**(7809): p. 434-443.<br>Kent, W.J., et al., *The human genome browser*<br>El Shamieh, S., et al., *Targe* 18. Kart, W.J., et al., The human genome browser at UCSC. Genome Res, 2002. 12(6): p. 996-1006.<br>
19. Kent, W.J., et al., The human genome browser at UCSC. Genome Res, 2002. 12(6): p. 996-1006.<br>
19. El Shamieh, S., et al., humans. Nature, 2020. **361**(7805). p. 434-443.<br>Kent, W.J., et al., *The human genome browser (El Shamieh, S., et al., Targeted next generation relatively common cause of autosomal recessiv*<br>**2015**: p. 485624. 19. Kent, W.J., et al., *The human genome browser at Oese*. Genome Res, 2002. 12(6): p. 950-1000.<br>20. El Shamieh, S., et al., *Targeted next generation sequencing identifies novel mutations in RP1 as*<br>2015: p. 485624.<br>2015 2015: p. 485624.<br>2015: p. 485624.<br>2015: p. 485624.  $\begin{array}{c} \textbf{2015: p. } \textbf{485624.} \end{array}$  $2015. p. 485624.$

- 
- 
- 
- 
- protein function using the SIFT algorithm. Nature Protocols, 2009. 4(7): p. 1073-1081.<br>
22. Adzhubei, I.A., et al., *A* method and server for predicting damaging missense mutations. Nature<br>
Methods, 2010. **7(4**): p. 248-24 protein function using the SiFT algorithm. Nature Protocols, 2009. 4(7): p. 1075-1001.<br>Adzhubei, I.A., et al., *A method and server for predicting damaging missense mutation*<br>Methods, 2010. **7(**4): p. 248-249.<br>Schwarz, J.M Methods, 2010. **7(4)**: p. 248-249.<br>
23. Schwarz, J.M., et al., *MutationTaster2: mutation prediction for the deep-sequencing age.* Nat<br>
Methods, 2014. **11(**4): p. 361-2.<br>
24. Stenson, P.D., et al., *The Human Gene Mutation* Methods, 2010. 7(4): p. 248-249.<br>Schwarz, J.M., et al., *MutationTas*<br>Methods, 2014. **11**(4): p. 361-2.<br>Stenson, P.D., et al., *The Human Crepository for clinical and molecul<br>medicine. Hum Genet, 2014. 133<br>Fokkema, I.F.,* Methods, 2014. 11(4): p. 361-2.<br>
24. Stenson, P.D., et al., The Human Gene Mutation Database: building a comprehensive mutatio<br>
repository for clinical and molecular genetics, diagnostic testing and personalized genomic<br>
m Methods, 2014. 11(4). p. 301-2.<br>Stenson, P.D., et al., *The Human<br>repository for clinical and molecu*<br>*medicine.* Hum Genet, 2014. 133<br>Fokkema, I.F., J.T. den Dunnen, a<br>sequence variation database usi.<br>8.<br>Koressaar, T. and repository for clinical and molecular genetics, diagnostic testing and personalized genomic<br>
medicine. Hum Genet, 2014. 133(1): p. 1-9.<br>
25. Fokkema, I.F., J.T. den Dunnen, and P.E. Taschner, *LOVD: easy creation of a locu* medicine. Hum Genet, 2014. 133(1): p. 1-9.<br>Fokkema, I.F., J.T. den Dunnen, and P.E. Taschner, *LOVD: easy creation of a locus-specific*<br>sequence variation database using an "LSDB-in-a-box" approach. Hum Mutat, 2005. 26(2): medicine. Hum Genet, 2014. 133(1): p. 1-9.<br>Fokkema, I.F., J.T. den Dunnen, and P.E. Tas<br>sequence variation database using an "LSDE<br>8.<br>Koressaar, T. and M. Remm, Enhancements<br>Primer3. Bioinformatics, 2007. 23(10): p. 12<br>Bir sequence variation database using an "LSDB-in-a-box" approach. Hum Mutat, 2005. 26(2)<br>
26. Koressaar, T. and M. Remm, *Enhancements and modifications of primer design program*<br>
Primer3. Bioinformatics, 2007. 23(10): p. 128
- 
- 
- sequence variation database using an "LSDB-in-a-box" approach. Hum Mutat, 2005. 20(2): p. 63-8.<br>
Roressaar, T. and M. Remm, Enhancements and modifications of primer design program<br>
Primer3. Bioinformatics, 2007. 23(10): p. - Ko<br>*Pri*<br>Bim<br>Gc<br>*th*<br>Cid<br>Hu<br>Br Primer3. Bioinformatics, 2007. 23(10): p. 1289-91.<br>
27. Birch, D.G., et al., *Visual function in patients with cone-rod dystrophy (CRD) associated w*<br> *mutations in the ABCA4(ABCR) gene.* Exp Eye Res, 2001. 73(6): p. 877-8 Frimers. Biomnomiatics, 2007. 23(10). p. 1209-91.<br>Birch, D.G., et al., *Visual function in patients with c*<br>mutations in the ABCA4(ABCR) gene. Exp Eye Res, *i*<br>Goetz, K.E., et al., *Genetic testing for inherited eye*<br>the e mutations in the ABCA4(ABCR) gene. Exp Eye Res, 2001. 73(6): p. 877-86.<br>
28. Goetz, K.E., et al., Genetic testing for inherited eye conditions in over 6,000 individuals throu<br>
the eyeGENE network. Am J Med Genet C Semin Me mutations in the ABCA4(ABCN) gene. Lxp Lye Res, 2001. 73(6): p. 877-86.<br>Goetz, K.E., et al., *Genetic testing for inherited eye conditions in over 6,00*<br>the eyeGENE network. Am J Med Genet C Semin Med Genet, 2020. 184(3)<br>C
- 
- 
- 
- 28. Communication and a proposed strategy for gene therapy.<br>
29. Cideciyan, A.V., et al., ABCA4 disease progression and a proposed strategy for gene therapy.<br>
29. Cideciyan, A.V., et al., ABCA4 disease progression and a pr the eyear. Increases and disease progression and a proposed strategy for gene their<br>Cideciyan, A.V., et al., ABCA4 idsease progression and a proposed strategy for gene their<br>Hum Mol Genet, 2009. 18(5): p. 931-41.<br>Briggs, C Hum Mol Genet, 2009. 18(5): p. 531-41.<br>Briggs, C.E., et al., *Mutations in ABCR (AE*<br>or cone-rod degeneration. Invest Ophtha<br>Del Pozo-Valero, M., et al., *Genotype-Phi*<br>With Biallelic ABCA4 Pathogenic Variants<br>Fujinami, K.
- 
- Hum Mol Genet, 2009. 18(5): p. 931-41.<br>
29. Briggs, C.E., et al., Mutations in ABCR (ABCA4) in patients with Stargardt macular degeneration<br>
29. Crease processor and a proposed strategy for the strategy for gene to the Bia or cone-rod degeneration. Invest Ophthalmol Vis Sci, 2001. 42(10): p. 2229-36.<br>
31. Del Pozo-Valero, M., et al., *Genotype-Phenotype Correlations in a Spanish Cohort of 506 Familie<br>
With Biallelic ABCA4 Pathogenic Variants* or cone-rod degeneration. Invest Ophthalmor vis Sci, 2001. 42(10): p. 2223-36.<br>Del Pozo-Valero, M., et al., *Genotype-Phenotype Correlations in a Spanish Coho*<br>With Biallelic ABCA4 Pathogenic Variants. Am J Ophthalmol, 202 With Biallelic ABCA4 Pathogenic Variants. Am J Ophthalmol, 2020. 219: p. 195-204.<br>
32. Fujinami, K., et al., Detailed genetic characteristics of an international large cohort of patients<br>
with Stargardt disease: ProgStar s With Biallelic ABCA4 Pathogenic Variants. Am J Ophthalmol, 2020. 219. p. 133-204.<br>Fujinami, K., et al., *Detailed genetic characteristics of an international large cohort of* with Stargardt disease: *ProgStar study report* with Stargardt disease: ProgStar study report 8. Br J Ophthalmol, 2019. 103(3): p. 390-397.<br>
33. Hu, F.Y., et al., ABCA4 Gene Screening in a Chinese Cohort With Stargardt Disease: Identificatio<br>
of 37 Novel Variants. Front MHT Stargardt disease: ProgStar stady report 8. Br 3 Ophthalmol, 2015. 103(3): p. 390-397.<br>Hu, F.Y., et al., ABCA4 Gene Screening in a Chinese Cohort With Stargardt Disease: Identifice<br>Alapati, A., et al., Molecular Diagno of 37 Novel Variants. Front Genet, 2019. 10: p. 773.<br>
34. Alapati, A., et al., Molecular Diagnostic Testing by eyeGENE: Analysis of Patients With Hereditary<br>
Retinal Dystrophy Phenotypes Involving Central Vision Loss. Inve by 37 Nover Vanams. Front Genet, 2013. 10: p. 773.<br>Alapati, A., et al., *Molecular Diagnostic Testing by ey*<br>Retinal Dystrophy Phenotypes Involving Central Visic<br>Visual Science, 2014. **55**(9): p. 5510-5521.<br>Tsybovsky, Y.,
- Stetinal Dystrophy Phenotypes Involving Central Vision Loss. Investigative Ophthalmology &<br>
Visual Science, 2014. 55(9): p. 5510-5521.<br>
35. Tsybovsky, Y., R.S. Molday, and K. Palczewski, The ATP-binding cassette transporte Visual Science, 2014. 55(9): p. 5510-5521.<br>Tsybovsky, Y., R.S. Molday, and K. Palczewski, *The ATP-binding cassette transporter ABCA4:*<br>*structural and functional properties and role in retinal disease.* Adv Exp Med Biol, Visual Science, 2014. 33(3): p. 3310-3321.<br>Tsybovsky, Y., R.S. Molday, and K. Palczew<br>structural and functional properties and ro<br>105-25.<br>Han, Z., S.M. Conley, and M.I. Naash, Gene<br>gene. Adv Exp Med Biol, 2014. 801: p. 719
- 
- 
- Structural and functional properties and role in retinal disease. Adv Exp Med Biol, 2010. 703<br>
35. Han, Z., S.M. Conley, and M.l. Naash, Gene therapy for Stargardt disease associated with AB<br>
36. Han, Z., S.M. Conley, and structural and functional properties and role in retinal disease. Adv Exp Med Biol, 2010. 703: p.<br>105-25.<br>Han, Z., S.M. Conley, and M.I. Naash, Gene therapy for Stargardt disease associated with ABCA4<br>gene. Adv Exp Med Bio ---<br>Han, Z.,<br>*gene.* Ac<br>*Massisi, Unsolvee*<br>Nassisi, I<br>**19**(8).<br>Boulang<br>*cone-roo* gene. Adv Exp Med Biol, 2014. **801**: p. 719-24.<br>
37. Nassisi, M., et al., Prevalence of ABCA4 Deep-Intronic Variants and Related Phenotype in An<br>
Unsolved "One-Hit" Cohort with Stargardt Disease. Int J Mol Sci, 2019. **20**( gene. Adv Exp Med Biol, 2014: 001: p. 719-24.<br>Nassisi, M., et al., *Prevalence of ABCA4 Deep-Ir*<br>Unsolved "One-Hit" Cohort with Stargardt Dise<br>Nassisi, M., et al., *Expanding the Mutation Spe*<br>Variants and Their Associated Unsolved "One-Hit" Cohort with Stargardt Disease. Int J Mol Sci, 2019. **20**(20).<br>
38. Nassisi, M., et al., Expanding the Mutation Spectrum in ABCA4: Sixty Novel Disease Causing<br>
Variants and Their Associated Phenotype in a Drisolved One-Hit Cohort with Stargardt Disease. Into Sur, 2019. 20(20).<br>Nassisi, M., et al., *Expanding the Mutation Spectrum in ABCA4*: *Sixty Novel Diseariants and Their Associated Phenotype in a Large French Stargardt*
- Variants and Their Associated Phenotype in a Large French Stargardt Cohort. Int J Mol Sci, 2<br>
19(8).<br>
Boulanger-Scemama, E., et al., Next-generation sequencing applied to a large French cone<br>
cone-rod dystrophy cohort: mut 19(8).<br>Boulanger-Scemama, E., et al., *Next-generation sequencing applied to a large French cone and*<br>cone-rod dystrophy cohort: mutation spectrum and new genotype-phenotype correlation.<br>Orphanet J Rare Dis, 2015. 10: p. 8 19<sub>(9)</sub>.<br>Boular<br>*cone-r*<br>Orpha<br>Burke,<br>ABCA4<br>Shanka<br>Investi 19. Bonder-rod dystrophy cohort: mutation spectrum and new genotype-phenotype correlation.<br>
2015. Burke, T.R., et al., Retinal phenotypes in patients homozygous for the G1961E mutation in the<br>
2016. Burke, T.R., et al., Re
- Cometation Barry Controlling States (Complete Complete Complete Complete Complete Controlling Density, et al., Retinal phenotypes in patients homozygous for the G1961E mutation in ABCA4 gene. Invest Ophthalmol Vis Sci, 201 Orphanet J Rare Dis, 2015. **10**: p. 85.<br>Burke, T.R., et al., *Retinal phenotypes*<br>ABCA4 gene. Invest Ophthalmol Vis S<br>Shankar, S.P., et al., *ABCA4 Sequence*<br>Investigative Ophthalmology & Visua
- ABCA4 gene. Invest Ophthalmol Vis Sci, 2012. **53**(8): p. 4458-67.<br>
Shankar, S.P., et al., ABCA4 Sequence Variations in Somali and North American Populations.<br>
Investigative Ophthalmology & Visual Science, 2006. 47(13): p. ABCA4 gene. Invest Ophthalmol Vis Sci, 2012. 33(0): p. 4458-67.<br>Shankar, S.P., et al., *ABCA4 Sequence Variations in Somali and No*<br>Investigative Ophthalmology & Visual Science, 2006. 47(13): p. 1 Investigative Ophthalmology & Visual Science, 2006. 47(13): p. 1699-1699.<br>
Somali and North American Populations in Somali and North American Populations.<br>
The North American Populations in Somali and North American Popula Investigative Ophthalmology & Visual Science, 2006. 47(13): p. 1699-1699.
- 
- 
- 
- Gella, W., et al., *G1961E mutant allele in the Stargardt disease gene ABCA4 causes bull's eye*<br>
maculopathy. Exp Eye Res, 2009. **89**(1): p. 16-24.<br>
43. Lewis, R.A., et al., *Genotype/Phenotype analysis of a photoreceptor*macuropatriy. Exp Eye Res, 2009. 89(1): p. 16-24.<br>Lewis, R.A., et al., *Genotype/Phenotype analysis c*<br>*transporter gene, ABCR, in Stargardt disease.* Am<br>Sun, H., P.M. Smallwood, and J. Nathans, *Biochen*<br>associated with h transporter gene, ABCR, in Stargardt disease. Am J Hum Genet, 1999.  $64(2)$ : p. 422-34.<br>
44. Sun, H., P.M. Smallwood, and J. Nathans, *Biochemical defects in ABCR protein variants*<br>
associated with human retinopathies. Na transporter gene, ABCR, in Stargard ansease. Am Start and Creater, 1999. Star, H., P. 422-34.<br>Sun, H., P.M. Smallwood, and J. Nathans, Biochemical defects in ABCR protein variants<br>associated with human retinopathies. Nat G 44. Sun, H., P. P. P. Superinted with human retinopathies. Nat Genet, 2000. 26(2): p. 242-6.<br>45. Garces, F., et al., Correlating the Expression and Functional Activity of ABCA4 Disease V With the Phenotype of Patients With associated with human retinopatines. Nat Genet, 2000. 20(2): p. 242-6.<br>Garces, F., et al., *Correlating the Expression and Functional Activity of All*<br>With the Phenotype of Patients With Stargardt Disease. Invest Ophthaln<br>
- 
- With the Phenotype of Patients With Stargardt Disease. Invest Ophthalmol Vis Sci, 2018. 59(6)<br>
p. 2305-2315.<br>
46. Passerini, I., et al., Novel mutations in of the ABCR gene in Italian patients with Stargardt<br>
disease. Eye With the Finctionary of Prainties With Stargardt Disease. Invest Ophthalmol Vis Sci, 2010. 39(6).<br>
Passerini, I., et al., *Novel mutations in of the ABCR gene in Italian patients with Stargardt*<br>
disease. Eye (Lond), 2010. Passerini, I., et<br>*disease.* Eye (L<br>Gerth, C., et al<br>*with known AE*<br>Clin Exp Ophth<br>Webster, A.R.,<br>2001. **42**(6): p.<br>Maugeri, A., et<br>recessive cone disease. Eye (Lond), 2010. 24(1): p. 158-64.<br>47. Gerth, C., et al., *Phenotypes of 16 Stargardt macular dystrophy/fundus flavimaculatus pair* with known ABCA4 mutations and evaluation of genotype-phenotype correlation. Gra disease. Lye (Lond), 2010. 24(1): p. 158-04.<br>Gerth, C., et al., *Phenotypes of 16 Stargardt*<br>with known ABCA4 mutations and evaluatic<br>Clin Exp Ophthalmol, 2002. 240(8): p. 628-3<br>Webster, A.R., et al., An analysis of alleli
- 
- 
- with known ABCA4 mutations and evaluation of genotype-phenotype correlation. Graefes Arch<br>Clin Exp Ophthalmol, 2002. 240(8): p. 628-38.<br>48. Webster, A.R., et al., An analysis of allelic variation in the ABCA4 gene. Invest Clin Exp Ophthalmol, 2002. 240(8): p. 628-38.<br>
Webster, A.R., et al., *An analysis of allelic variation in the ABCA4 gene.* Invest Ophthalmol Vis Sc<br>
2001. 42(6): p. 1179-89.<br>
Maugeri, A., et al., *Mutations in the ABCA4 (* EMERAP Ophthalmol, 2002. 240(0): p. 028-30.<br>Webster, A.R., et al., An analysis of allelic varia<br>2001. 42(6): p. 1179-89.<br>Maugeri, A., et al., Mutations in the ABCA4 (Alerecessive cone-rod dystrophy. Am J Hum Gene<br>Bungert, 2001. 42(6): p. 1179-89.<br>
49. Maugeri, A., et al., Mutations in the ABCA4 (ABCR) gene are the major cause of autosomal<br>
recessive cone-rod dystrophy. Am J Hum Genet, 2000. 67(4): p. 960-6.<br>
50. Bungert, S., L.L. Molday, an 2001. 42(0): p. 1173-83.<br>Maugeri, A., et al., *Muta:*<br>recessive cone-rod dystro<br>Bungert, S., L.L. Molday,<br>transporter ABCR and its<br>linked glycosylation sites<br>Singh, H.P., et al., *Homoz*<br>recessive retinal dystropl<br>Papaioan Francessive cone-rod dystrophy. Am J Hum Genet, 2000. 67(4): p. 960-6.<br>
50. Bungert, S., L.L. Molday, and R.S. Molday, *Membrane topology of the ATP binding cassette*<br>
transporter ABCR and its relationship to ABC1 and rela recessive cone-rod dystrophy. Am J Hum Genet, 2000: 67(4): p. 960-6.<br>Bungert, S., L.L. Molday, and R.S. Molday, *Membrane topology of the Aransporter ABCR and its relationship to ABC1 and related ABCA transplinked glycosyl*
- 
- 
- 
- transporter ABCR and its relationship to ABC1 and related ABCA transporters: identification<br>linked glycosylation sites. J Biol Chem, 2001. 276(26): p. 23539-46.<br>
Singh, H.P., et al., Homozygous null mutations in the ABCA4 miked giftersylation sites. J biol Chem, 2001. 270(20): p. 23333-46.<br>Singh, H.P., et al., *Homozygous null mutations in the ABCA4 gene in*<br>recessive retinal dystrophy. Am J Ophthalmol, 2006. 141(5): p. 906-<br>Papaioannou, M. Francessive retinal dystrophy. Am J Ophthalmol, 2006. 141(5): p. 906-13.<br>
52. Papaioannou, M., et al., An analysis of ABCR mutations in British patients with recessive retinal<br>
dystrophies. Invest Ophthalmol Vis Sci, 2000. recessive retinar aystrophy. Am J Ophthalmol, 2000. 141(5): p. 900-13.<br>Papaioannou, M., et al., An analysis of ABCR mutations in British patien<br>dystrophies. Invest Ophthalmol Vis Sci, 2000. 41(1): p. 16-9.<br>September, A.V., dystrophies. Invest Ophthalmol Vis Sci, 2000. 41(1): p. 16-9.<br>
53. September, A.V., et al., Mutation spectrum and founder chromosomes for the ABCA4 gene in<br> *South African patients with Stargardt disease.* Invest Ophthalmo dystropmes. Invest Ophthalmol Vis Sci, 2000. 41(1): p. 10-9.<br>September, A.V., et al., *Mutation spectrum and founder chrc*<br>South African patients with Stargardt disease. Invest Ophtha<br>Smaragda, K., et al., *Mutation Spectr* South African patients with Stargardt disease. Invest Ophthalmol Vis Sci, 2004. 45(6): p. 1705<br>
54. Smaragda, K., et al., Mutation Spectrum of the ABCA4 Gene in a Greek Cohort with Stargardt<br>
Disease: Identification of Nov South African patients with Stargardt assesse. Invest Ophthalmol Vis Sci, 2004. 45(6): p. 1705-11.<br>Smaragda, K., et al., Mutation Spectrum of the ABCA4 Gene in a Greek Cohort with Stargardt<br>Disease: Identification of Novel Disease: Identification of Novel Mutations and Evidence of Three Prevalent Mutated Alleles. J<br>Ophthalmol, 2018. 2018: p. 5706142.<br>55. Weisschuh, N., et al., Molecular and clinical analysis of 27 German patients with Leber<br>
- congenital amaurosis. PLOS ONE, 2018. 13(12): p. e0205380. Ophthalmol, 2018. **2018**: p. 5706142.<br>Ophthalmol, 2018. **2018**: p. 5706142.<br>Weisschuh, N., et al., *Molecular and clinical analysis of 27 German patients with Leber*<br>congenital amaurosis. PLOS ONE, 2018. **13**(12): p. e0205 Ophthalmol, 2018. 2018. p. 5700142.<br>Weisschuh, N., et al., *Molecular and congenital amaurosis.* PLOS ONE, 2018.  $\emph{congenital amaurusis. PLOS ONE, 2018.}$  **13**(12):  $\emph{p.}$  e0205380. congenital amaurosis. PLOS ONE, 2018. 13(12): p. e0205380.<br>Professor



Figure 1. Pedigrees of seven families with mutations in ABCA4 gene. White symbols represent members who are unaffected. Symbols in black denote affected individuals. Males and females are represented by square and round symbols, respectively. Individuals who have died are denoted by a slash. Double horizontal lines represent consanguineous marriages. M: mutation.



Figure 2: Color fundus photographs (a), fluorescein angiography (b), optical coherence tomography (OCT) scans (c), and autofluorescence pictures (d) of patients F3:I3, F9:I9.1, F31:I31, F37:I37,F41:I41, F56:I56 and F58:I58. OD = oculus Dexter; OS: ocular sinister.



## Table 1. Clinical results identified in eight Lebanese patients with inherited retinal disorders.

STGD: Stargardt disease; RCD: rod cone dystrophy; ERG: electroretinogram; OCT: optical<br>coherence tomography; EOG: Electrooculogram; NA: not available. Electrooculogram;



Table 2. ABCA4 mutations in seven Lebanese families with different forms of inherited retinal diseases.



STGD: stargardt diseases; CRD: cone rod dystrophy; RP: Retinitis pigmentosa; hom: homozygous; rs: reference SNP.